Skip to main content
Signal8

Jaguar Health Reports Third Quarter 2026 Financials

$JAGXPress releaseNov 16, 2026, 9:00 AM ETRead the release

Jaguar Health reported Q3 2026 total net revenue of $2.3 million, down 24% year-over-year, with prescription product revenue falling 81.9% to $0.55 million after licensing U.S. commercialization of Mytesi and Canalevia-CA1 to Future Pak. Net loss narrowed 39.6% to $5.8 million from $9.6 million a year ago, and non-GAAP recurring EBITDA loss improved to $5.0 million from $9.0 million, driven by roughly $2.0 million in operating expense reductions including dissolution of the salesforce.

Key figures

Revenue
2343000
Revenue Yoy
-24.0%
Product revenue net
551000
Product revenue yoy
-81.9%
Q2 2026 product revenue
1200000
License grant revenue net
1792000
Prior year product revenue
3041000

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.